Expertise
Lxbio AB is an end-to-end antibody discovery service provider, able to help our clients from early discovery up to cell line development.
Lxbio Pharmaceuticals is a clinical-stage biotech advancing first-in-class bacteriophage therapies for high-burden infectious diseases across diabetic foot infections (DFI), dermatology, and ophthalmology.
The company also provides antibody discovery services through its CRO arm, Lxbio AB. This part of the company specializes in advancing therapeutic and research antibody development, offering end-to-end antibody discovery, engineering and characterization services. From automated high-throughput screening to advanced cell line development, Lxbio AB leverages cutting-edge tools and methodologies to deliver scalable, high-quality antibody solutions tailored to your project. 𝐘𝐨𝐮𝐫 𝐈𝐝𝐞𝐚, 𝐘𝐨𝐮𝐫 𝐏𝐫𝐨𝐣𝐞𝐜𝐭, 𝐎𝐮𝐫 𝐌𝐢𝐬𝐬𝐢𝐨𝐧. 𝐓𝐞𝐥𝐥 𝐮𝐬 𝐰𝐡𝐚𝐭 𝐲𝐨𝐮 𝐰𝐚𝐧𝐭; 𝐰𝐞 𝐰𝐢𝐥𝐥 𝐝𝐞𝐥𝐢𝐯𝐞𝐫 𝐭𝐨 𝐲𝐨𝐮.
What is your business/industry sector?
Expertise
Lxbio AB is an end-to-end antibody discovery service provider, able to help our clients from early discovery up to cell line development.